Education
About Us
Working with TipRanks
Follow Us
Checkpoint Therapeutics (CKPT)
:CKPT
CKPT Stock Chart & Stats
$4.26
$0.00(0.00%)
―
--
Day’s Range― - ―
52-Week Range― - ―
Previous CloseN/A
VolumeN/A
Average Volume (3M)N/A
Market Cap
N/A
Enterprise ValueN/A
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)―
BetaN/A
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares OutstandingN/A
10 Day Avg. VolumeN/A
30 Day Avg. VolumeN/A
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
P/FCF RatioN/A
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Checkpoint Therapeutics News
CKPT FAQ
What was Checkpoint Therapeutics’s price range in the past 12 months?
Currently, no data Available
What is Checkpoint Therapeutics’s market cap?
Currently, no data Available
When is Checkpoint Therapeutics’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Checkpoint Therapeutics’s earnings last quarter?
Currently, no data Available
Is Checkpoint Therapeutics overvalued?
According to Wall Street analysts Checkpoint Therapeutics’s price is currently Undervalued.
Does Checkpoint Therapeutics pay dividends?
Checkpoint Therapeutics does not currently pay dividends.
What is Checkpoint Therapeutics’s EPS estimate?
Checkpoint Therapeutics’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Checkpoint Therapeutics have?
Currently, no data Available
What happened to Checkpoint Therapeutics’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of Checkpoint Therapeutics?
Currently, no hedge funds are holding shares in CKPT
Company Description
Checkpoint Therapeutics
Checkpoint Therapeutics, Inc. (CKPT) is a clinical-stage biopharmaceutical company specializing in the development and commercialization of immuno-oncology and targeted therapy treatments for patients with solid tumor cancers. The company focuses on developing a robust pipeline of novel combination therapies aimed at treating various cancer indications. Checkpoint Therapeutics' lead product candidates include cosibelimab, an anti-PD-L1 antibody, and CK-101, a third-generation epidermal growth factor receptor (EGFR) inhibitor.
Ownership Overview
―
Insiders
<0.01%
Mutual Funds
― Other Institutional Investors
100.00% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---